On August 16, Lindsay Bealor Greenleaf, the federal and state policy solution leader at ADVI Health, recently discussed CMS’ drug pricing announcement under the Inflation Reduction Act (IRA) in an interview with Pharmacy Times.

In the article, Analysis: What to Expect From CMS’ Inflation Reduction Act Drug Pricing Announcement, Lindsay provides insights into CMS’ pricing decisions for the drugs selected last year.

She highlights the potential cost savings for both pharmacists and their patients, noting that these reductions could make medications more affordable. Lindsay also explains the complex process that CMS uses to negotiate these prices, offering a clear perspective on the broader impact of the IRA on drug pricing and healthcare access in the United States.

Hear Lindsay’s insights in Pharmacy Times.